25 July 2025 French diabetes and obesity specialist Adocia was trading 45% higher late Friday following its partner Tonghua Dongbao’s release of positive topline results from the Phase III trial of BioChaperone Lispro (THDB0206 injection), a novel ultra-rapid insulin formulation.
As many as 19 of the top 20 publicly-traded global biopharma companies reported revenue growth in 2024, with an overall 7.9% year-on-year (YoY) increase in aggregate revenue to $880.4 billion, reveals GlobalData. 29 July 2025
Shares in CervoMed were up 6% Monday lunchtime after the US company announced positive 32-week data from the extension phase of the Phase IIb RewinD-LB trial showing that oral neflamapimod continues to slow disease progression and demonstrate an effect on a plasma marker of neurodegeneration in dementia with Lewy bodies (DLB). 28 July 2025
US clinical-stage oncology focused biotech Celcuity saw its shares skyrocket 180% to $38.59 in early trading as it announced positive trial data for its lead candidate gedatolisib. 28 July 2025
Hong Kong-based biotech Neuco United and Shanghai Fosun Pharmaceutica have signed an exclusive licensing agreement for the manufacturing and commercialization of AR1001 in Greater China, encompassing the Chinese mainland, Hong Kong and Macau. 28 July 2025
Jiangsu Hengrui Pharmaceuticals shares rallied to their highest level in four years – leaping 10% to 62.04 renminbi - after UK pharma major GSK announced a deal with the Chinese company. 28 July 2025
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved US biotech Biogen’s Qalsody (tofersen) to treat adults with amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 (an enzyme called superoxide dismutase 1) gene – a rare, inherited form of motor neurone disease (MND). 28 July 2025
World Hepatitis Day, marked each year on July 28, is shining a light on what GlobalData calls an “urgent need” for a renewed push to tackle viral hepatitis as mortality rises worldwide. The disease remains among the deadliest infectious threats, affecting more than 300 million people globally. 28 July 2025
A new European project, called Greg, has been launched to tackle long-standing challenges around the use of real-world data and evidence in medicines, medical devices, and drug-device combinations. 28 July 2025
Boehringer Ingelheim and Re-Vana Therapeutics, a USA and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases. 28 July 2025
China has recently approved the first locally developed obesity drug Xinermei (mazdutide), marking a critical milestone in the country’s obesity treatment landscape. 28 July 2025
For millions in low- and middle-income countries (LMICs), lifesaving medicines remain out of reach. While the pharmaceutical industry continues to deliver record-breaking innovation, access to those breakthroughs is often determined by cruel lotteries of geography and income. 28 July 2025
The information portal on the entry of new medicines and indications shows the number of new medicines and indications (expanding the possibilities of treating various types of diseases with given medicines) included in the standard system of reimbursement from public health insurance, the Slovak pharma trade group AIFP noted in a website posting. 28 July 2025
The US Food and Drug Administration (FDA) has notified Bayer that it has extended the review period for the New Drug Application (NDA) for elinzanetant, the first neurokinin 1 and neurokinin 3 receptor antagonist for the treatment of moderate to severe vasomotor symptoms (VMS; also known as hot flashes) due to menopause. 26 July 2025
US pharma major Bristol Myers Squibb revealed it has appointed Dr Cristian Massacesi as executive vice president, chief medical officer and head of development, effective August 1, 2025. 26 July 2025
French diabetes and obesity specialist Adocia was trading 45% higher late Friday following its partner Tonghua Dongbao’s release of positive topline results from the Phase III trial of BioChaperone Lispro (THDB0206 injection), a novel ultra-rapid insulin formulation. 25 July 2025
The European Medicines’ (EMA) human medicines committee (CHMP) has recommended seven novel medicines for approval at its July 2025 meeting. 25 July 2025
Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed under the trade name Wegovy for obesity, is emerging as a promising candidate for neurological conditions. 25 July 2025
The Trump administration has asked the US Supreme Court to allow the National Institutes of Health (NIH) to resume canceling hundreds of research grants supporting work on health equity, racial disparities, and other diversity-related public health initiatives. 25 July 2025
The attention-deficit/hyperactivity disorder (ADHD) market across the seven major markets (7MM) is forecast to decline at a negative compound annual growth rate (CAGR) of 0.9% from $11.9 billion in 2022 to $10.9 billion in 2032. 4 June 2024
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals today announced results from the company’s MOTION pivotal Phase III study of vimseltinib in patients with Tenosynovial Giant Cell Tumor TGCT) in an oral presentation at ASCO. 3 June 2024
Privately-held neurology company Tris Pharma has received approval from the US Food and Drug Administration for Onyda XR (clonidine hydrochloride). 3 June 2024
CSL Seqirus is set to complete the fill and finish process for pre-pandemic vaccine to support the US government’s outbreak and preparedness response. 3 June 2024
At the 2024 annual meeting of the American Society of Clinical Oncology (ASCO), Bristol Myers Squibb has announced promising results from the Phase III KRYSTAL-12 study. 3 June 2024
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
US cancer-focussed firm Karyopharm Therapeutics presented updated exploratory subgroup analyses from the Phase III SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the American Society of Clinical Oncology (ASCO). 2 June 2024
Last week, the US Court of Appeals for the District of Columbia (DC) ruled that Section 340B of the Public Health Service Act does not prohibit pharmaceutical manufacturers from imposing conditions on the distribution of discounted drugs to covered entities in the program, noted Sophia Gaulkin and Alan Kirschenbaum of law firm Hyman Phelps & McNamara. 1 June 2024
Privately-held UK clinical-stage firm Soterios Pharma has announced positive multi-dose Phase II trial evaluating STS-01 as a treatment for mild/moderate alopecia areata (AA). 31 May 2024
Biogen has announced European approval for Qalsody (tofersen), for certain amyotrophic lateral sclerosis (ALS) patients, under exceptional circumstances. 31 May 2024
Danish allergy immunotherapy specialist ALK Abell today revealed that its European regulatory filing for Itulazax (tree sublingual allergy immunotherapy [SLIT] tablet) in young children has been accepted for review by the relevant health authorities. 30 May 2024
US genetic diseases and cancer drug developer BridgeBio Pharma has announced positive results of five new analyses of clinical endpoint events from its Phase III ATTRibute-CM study of acoramidis in transthyretin amyloidosis cardiomyopathy (ATTR-CM). 30 May 2024
Globally, the devastating and widespread impact of neurological disorders like Alzheimer's disease, epilepsy, Parkinson’s disease and depression is only getting worse. 30 May 2024
Johnson & Johnson has announced positive results from the Phase III MDD3001 trial for seltorexant, a selective orexin-2 receptor antagonist. 30 May 2024
New research published in Nature Communications shows another potential application for GLP-1 agonists, adding to established benefits in type 2 diabetes, obesity and heart disease. 30 May 2024
After more than 30 years with neuroscience-focused biopharma Neurocrine Biosciences, founder and chief executive Kevin Gorman is to retire in October - albeit staying on as a board member. 29 May 2024